These three companies reported strong FY26/FY27 updates with earnings growth, strategic actions, new contracts, improved outlooks and shareholder returns supporting their business performance.

Guzman y Gomez Limited (ASX: GYG) On 21 August 2026, announced its FY26 results for the year ended 30 June 2026. The network sales increased by 17.9% to $1,378 million. The underlying EBITDA improved by 28.7% to $85.0 million. The net profit after tax increased by 31.6% to $40.6 million, while the underlying net profit after tax stood at $53.4 million. There was a total of 284 restaurants spread out in Australia, Singapore and Japan with 35 new restaurants opened during the year.

Its Australian network sales increased 17.9% to $1,290.7 million. The growth came from 32 new restaurants and stronger performance across its sales drivers. The company had 117 Australian restaurants in its development pipeline with commercial terms agreed with about 85% planned as drive thru sites.

GYG confirmed that its exit from the US operations was complete. Closure costs were at the lower end of the guided US$30–40 million range. Statutory NPAT was a loss of $26.7 million mainly due to one-off US impairment and closure costs. At year end, GYG held $171 million in cash and term deposits with no debt.

GYG expects to open 35 new restaurants in Australia during FY27, while comp sales growth is expected to remain at mid-single digit levels. Underlying EBITDA margin is forecast at 6.7–6.9%. GYG declared a fully franked FY26 dividend of 48.0 cents per share including a 14.4 cents special dividend and approved a further $100M on market share buyback.

James Hardie Industries plc (ASX: JHX) On 21 August 2026 announced the sale of its European Fermacell business to Holcim for €840 million in cash about US$980 million. It also plans to close its European fiber cement business, subject to required legal, regulatory and employee consultations.

On 6 August 2026, the company reported first-quarter FY27 net sales of $1.475 billion, up 64% year on year, while pro forma sales rose 12%. Siding & Trim sales reached $860 million, with North American Fiber Cement up 20% organically. Net income was $104 million and Adjusted EBITDA was $422 million.

FY27 guidance was raised to pro forma sales growth of 5.9% to 9.0% and Adjusted EBITDA growth of 7.4% to 13.7%. Free cash flow guidance stayed above $500 million. Cost synergies were ahead of schedule, revenue synergies remained on track, and certain non-GAAP measures were revised to exclude share-based compensation costs.

Pro Medicus Limited (ASX: PME) On 21 August 2026, announced a 7-year, A$25 million contract with Valley Health in the US. It covers Visage 7 Viewer, Workflow, Open Archive and Cardiology Imaging with the platform to be delivered through the cloud.

On 18 August 2026, PME reported FY26 revenue of $261.7 million, up 22.9%, underlying EBIT of $196.1 million, up 24.4%, and underlying NPAT of $144.7 million, up 24.1%. Cash and other financial assets reached $252.3 million, with no debt. A fully franked final dividend of 37 cents per share was declared.

During FY26, PME signed 10 contracts worth A$407 million and renewed six contracts worth A$141 million.